In the latest update of Vertex's VX-880, three patients at high hypoglycemia risk achieved A1c < 7% with no severe ...

Vertex Pharmaceuticals will use Orum Therapeutics’ dual-precision targeted protein degradation (TPD²®) technology platform to ...

Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in ...

the newly engrafted islet cells produce enough insulin for the body's requirements, ending the need for treatments like supplemental insulin injections. Per the readout from Vertex's clinical ...

Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute ...

In the suit, Vertex argues HHS’ stance forces a “Hobson’s choice” on people with sickle cell seeking to undergo the potentially curative treatment.

The firm is asking a court to determine that its program to pay for fertility treatments for patients on Casgevy doesn't violate anti-kickback and inducement laws.

Vertex Pharmaceuticals said Friday. All but one reduced or eliminated the need to inject insulin over those three months and three people followed for one year no longer needed to inject insulin ...

The deal, valued at more than $325 million, gives Vertex the right to use Orum's technology to develop new targeted conditioning agents for its gene therapies.

The case is Vertex v. US Department of Health and Human Services, 24-cv-02046, US District Court, District of Columbia ...

Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...